CLDX
Price
$27.50Alerts
Change
-$0.46 (-1.65%)
Updated
Nov 20, 11:39 AM (EDT)
Capitalization
2.35B
101 days until earnings call
Intraday BUY SELL Signals
LRMR
Price
$3.12Alerts
Change
-$0.10 (-3.11%)
Updated
Nov 20, 11:50 AM (EDT)
Capitalization
248.28M
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLDX vs LRMR

CLDX vs LRMR Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Nov 07, 2026

Which Stock Would AI Choose? Celldex Therapeutics (CLDX) vs. Larimar Therapeutics (LRMR) Stock Comparison

Key Takeaways

  • CLDX (Celldex Therapeutics) is a clinical-stage immunology biotech advancing its lead antibody candidate, barzolvolimab, through late-stage trials in chronic spontaneous urticaria (CSU, a chronic hives condition).
  • LRMR (Larimar Therapeutics) is an earlier-stage rare-disease biotech focused on nomlabofusp for Friedreich's ataxia (a progressive neurological disorder).
  • Both companies are pre-revenue and loss-making, but they differ sharply in market value, pipeline breadth, and stage of clinical validation.
  • CLDX carries a market capitalization of roughly $2.3 billion, while LRMR is a micro-cap near $250 million, reflecting materially different risk and liquidity profiles.
  • Tickeron AI Verdict: CLDX is the favored ticker, reflecting its more advanced clinical data, broader pipeline, and stronger relative trend stability.
  • For additional context, explore CLDX Major News and CLDX Today's Price Move, as well as LRMR Major News and LRMR Today's Price Move.
  • To see how AI-driven systems rank these and other tickers, explore Trending AI Robots.

Introduction

This stock comparison examines two clinical-stage biotechnology companies at different points in their development journeys. CLDX and LRMR both depend on clinical-trial outcomes and regulatory milestones rather than recurring product revenue, making them relevant to investors who follow the healthcare and biotech sector. Understanding their relative performance, market positioning, and momentum can help traders and longer-term investors assess where each name stands in the current environment. Because both carry binary, event-driven risk profiles, the comparison centers on observable factors such as clinical progress, cash runway, market capitalization, and recent price behavior rather than on short-term earnings.

CLDX Overview and Recent Performance

CLDX develops therapeutic antibodies targeting mast cells, a type of immune cell involved in allergic and inflammatory conditions. Its lead program, barzolvolimab, is being studied across several indications, most notably chronic spontaneous urticaria. In recent weeks, the stock has been shaped by two contrasting developments: positive topline Phase 3 results from the EMBARQ-CSU1 and EMBARQ-CSU2 trials, where barzolvolimab met its primary and key secondary endpoints, alongside a separate Phase 2 miss in prurigo nodularis (a chronic itchy skin condition) that led the company to discontinue development in that indication. Market sentiment has reflected this mixed picture, with shares trading well below their 52-week high despite a broadly bullish analyst consensus and price targets meaningfully above the current price. The company reported a wider net loss in recent quarters as it funds late-stage trials and pre-commercial activities, with a regulatory filing targeted for 2027.

LRMR Overview and Recent Performance

LRMR is a clinical-stage biotech developing nomlabofusp, a protein-replacement therapy for Friedreich's ataxia, a rare, progressive, and life-limiting genetic disease with limited treatment options. Recent activity has centered on the regulatory path: the company submitted the first module of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration, following alignment on a novel surrogate endpoint and continued open-label data showing sustained frataxin (a key protein) increases. Management changes have also drawn attention, including the appointment of a new president and chief operating officer. The stock has been volatile, trading in a wide 52-week range and pulling back in recent weeks after earlier gains. As a single-asset, micro-cap company, its performance is highly sensitive to clinical and regulatory news, and it remains pre-revenue with a projected cash runway into 2027.

Trending AI Robots

Tickeron operates a large ecosystem of AI trading bots spanning thousands of tickers, each with its own strategy, timeframe, and performance profile. Because not every bot suits every market regime, Tickeron curates a focused selection of Trending AI Robots to highlight the systems most aligned with current conditions. These bots vary in trading style, holding period, and the basket of tickers they monitor, giving investors a way to compare quantitative approaches across different asset classes. The curated list is updated to reflect shifting market dynamics, and it offers a practical starting point for those interested in data-driven, rules-based strategies. Exploring the page can help you understand how automated systems are evaluating momentum, trend consistency, and relative strength right now.

Head-to-Head Comparison

While both companies are biotechnology developers, their market positioning differs in several important ways. CLDX operates with a larger balance sheet, a lead asset already through positive late-stage data in its anchor indication, and a pipeline extending into multiple mast-cell-driven diseases. Its risk is weighted toward execution, safety monitoring, and the distance to a 2027 regulatory filing. LRMR, by contrast, is a smaller, single-asset company whose valuation hinges almost entirely on nomlabofusp's regulatory progress in a rare-disease market. This concentration offers potentially higher reward if approval succeeds but carries greater binary risk. On momentum, both stocks have retreated from recent highs, but CLDX's higher market capitalization, broader analyst coverage, and more advanced data set give it comparatively stronger trend consistency and lower single-event vulnerability than LRMR.

Tickeron AI Verdict

Based on observable factors such as clinical-stage progression, pipeline breadth, market capitalization, and relative trend stability, Tickeron's AI framework would currently favor CLDX over LRMR. The presence of positive Phase 3 data, a diversified development program, and a larger liquidity base positions CLDX with a more consistent relative profile, whereas LRMR remains more dependent on a single asset and its regulatory milestones. This is a probabilistic assessment grounded in recent data and market positioning, not a definitive forecast of future returns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
CLDX vs. LRMR commentary
Nov 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and LRMR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CLDX with price predictions
Nov 19, 2026

CLDX in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 09, 2026

CLDX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDX as a result. In 69 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for CLDX turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

The 50-day moving average for CLDX moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 156 of 212 cases where CLDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.596). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (443.347).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for LRMR with price predictions
Nov 19, 2026

Aroon Indicator for LRMR shows an upward move is likely

LRMR's Aroon Indicator triggered a bullish signal on November 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 152 similar instances where the Aroon Indicator showed a similar pattern. In 129 of the 152 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LRMR's RSI Indicator exited the oversold zone, 24 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LRMR as a result. In 79 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for LRMR just turned positive on October 21, 2026. Looking at past instances where LRMR's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.

LRMR moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +7.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where LRMR advanced for three days, in 214 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LRMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

LRMR broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LRMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.949) is normal, around the industry mean (3.596). P/E Ratio (-1.189) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LRMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CLDX vs LRMR: Fundamental Ratings
CLDX
LRMR
OUTLOOK RATING
1..100
8523
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6239
P/E GROWTH RATING
1..100
2813
SEASONALITY SCORE
1..100
4442

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (58) in the null industry is somewhat better than the same rating for CLDX (99) in the Biotechnology industry. This means that LRMR’s stock grew somewhat faster than CLDX’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as CLDX (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's SMR Rating (98) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that CLDX’s stock grew similarly to LRMR’s over the last 12 months.

LRMR's Price Growth Rating (39) in the null industry is in the same range as CLDX (62) in the Biotechnology industry. This means that LRMR’s stock grew similarly to CLDX’s over the last 12 months.

LRMR's P/E Growth Rating (13) in the null industry is in the same range as CLDX (28) in the Biotechnology industry. This means that LRMR’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXLRMR
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 20, 2026
Stock price -- (CLDX: $27.96 vs. LRMR: $3.22)
Brand notoriety: CLDX and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 52% vs. LRMR: 66%
Market capitalization -- CLDX: $2.35B vs. LRMR: $248.28M
CLDX [@Biotechnology] is valued at $2.35B. LRMR’s [@Biotechnology] market capitalization is $248.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 1 FA rating(s) are green while LRMR’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 1 green, 4 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 4 TA indicator(s) are bullish while LRMR’s TA Score has 6 bullish TA indicator(s).

  • CLDX’s TA Score: 4 bullish, 5 bearish.
  • LRMR’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than CLDX.

Price Growth

CLDX (@Biotechnology) experienced а -2.00% price change this week, while LRMR (@Biotechnology) price change was +19.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.71%. For the same industry, the average monthly price growth was -12.21%, and the average quarterly price growth was -24.74%.

Reported Earning Dates

CLDX is expected to report earnings on Mar 01, 2027.

LRMR is expected to report earnings on Mar 19, 2027.

Industries' Descriptions

@Biotechnology (-3.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with STOK. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then STOK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+1.49%
STOK - CLDX
48%
Loosely correlated
+0.90%
MGTX - CLDX
47%
Loosely correlated
-2.16%
EDIT - CLDX
46%
Loosely correlated
-3.39%
VYGR - CLDX
46%
Loosely correlated
-3.59%
BCYC - CLDX
45%
Loosely correlated
-1.93%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with AMLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-0.16%
AMLX - LRMR
45%
Loosely correlated
-1.58%
CLDX - LRMR
44%
Loosely correlated
+1.49%
VIR - LRMR
44%
Loosely correlated
-3.06%
MLTX - LRMR
42%
Loosely correlated
+2.22%
VYGR - LRMR
41%
Loosely correlated
-3.59%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HAPS38.44N/A
N/A
Harbor Human Capital Factor US Small Cap ETF (HAPS)
MYMG24.70N/A
N/A
State Street My2027 Municipal Bond ETF (MYMG)
QMAR36.50-0.50
-1.34%
FT Vest Nasdaq-100 Buffer ETF - March (QMAR)
DIVO44.66-0.81
-1.78%
Amplify CWP Enhanced Dividend Income ETF (DIVO)
PFI55.32-1.22
-2.16%
Invesco Dorsey Wright Financial Momentum ETF (PFI)